纤溶酶原激活物抑制物-1与糖尿病肾病关系的研究进展

被引：2

作者：

董崇周

叶山东

机构：

[1] 安徽医科大学附属省立医院安徽省立医院内分泌科

来源：

国际泌尿系统杂志 | 2009年 / 01期

关键词：

糖尿病肾病; 纤溶酶原激活物抑制物1;

D O I：

暂无

中图分类号：

R692 [肾疾病];

学科分类号：

100221 [泌尿外科学];

摘要：

糖尿病肾病(diabetic nephropathy,DN)是糖尿病(diabetes mellitus,DM)最常见的慢性并发症之一,细胞实验、动物实验、临床研究均证实纤溶酶原激活物抑制物-1(Plasminogen activator inhibitor-1,PAI-1)是其重要的致病因素之一。糖尿病(DM)情况下,高血糖、血管紧张素II(Angiotensin Ⅱ,Ang Ⅱ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、非酶促糖基化终末产物(advanced glycation en-doproducts,AGEs)和醛固酮的水平升高等均可上调全身和肾脏局部的PAI-1表达,导致肾小球、肾间质纤维化和肾小管损害,促进DN的发生发展。血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体阻断剂(ARB)、噻唑烷二酮类(thiazolidinediones,TZDs)、双胍类、调脂药、醛固酮受体拮抗剂和抗氧化剂等药物可不同程度阻断上述途径,从而有助防止、延缓DN的发展。

引用

共 13 条

[1]

The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients [J].

Ersoy, Canan ;

Kiyici, Sinem ;

Budak, Ferah ;

Oral, Barbaros ;

Guclu, Metin ;

Duran, Cevdet ;

Selimoglu, Hadi ;

Erturk, Erdinc ;

Tuncel, Ercan ;

Imamoglu, Sazi .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 81 (01) :56-60

[2]

Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome [J].

Derosa, G. ;

D'Angelo, A. ;

Ragonesi, P. D. ;

Ciccarelli, L. ;

Piccinni, M. N. ;

Pricolo, F. ;

Salvadeo, S. ;

Montagna, L. ;

Gravina, A. ;

Ferrari, I. ;

Galli, S. ;

Paniga, S. ;

Cicero, A. F. G. .

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2006, 34 (05) :545-555

[3]

Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1 [J].

Chen, Lu-Lu ;

Zhang, Jiao-Yue ;

Wang, Bao-Ping .

VASCULAR PHARMACOLOGY, 2006, 44 (05) :309-315

[4]

Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans [J].

Enomoto, Mika ;

Adachi, Hisashi ;

Yamagishi, Sho-ichi ;

Takeuchi, Masayoshi ;

Furuki, Kumiko ;

Hino, Asuka ;

Hiratsuka, Akiko ;

Takajo, Yoshinori ;

Imaizumi, Tsutomu .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (07) :912-917

[5]

Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes [J].

Festa, A ;

Williams, K ;

Tracy, RP ;

Wagenknecht, LE ;

Haffner, SM .

CIRCULATION, 2006, 113 (14) :1753-1759

[6]

Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation [J].

Liu, HB ;

Hu, YS ;

Medcalf, RL ;

Simpson, RW ;

Dear, AE .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 334 (01) :30-37

[7]

Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus [J].

Ludwig, S ;

Dharmalingam, S ;

Erickson-Nesmith, S ;

Ren, S ;

Zhu, FQ ;

Ma, GPM ;

Zhao, RZ ;

Fenton, JW ;

Ofosu, FA ;

te Velthuis, H ;

van Mierlo, G ;

Shen, GX .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 70 (02) :110-118

[8]

Renal synthesis of urokinase type-plasminogen activator; its receptor; and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: Modulation by angiotensin-converting–enzyme inhibitor.[J].Miyazaki Kenichi;Miyazaki Masanobu;Koji Takehiko;Tsukasaki Shoko;Furusu Akira;Abe Katsushige;Harada Takashi;Ozono Yoshiyuki;Kohno Shigeru.The Journal of Laboratory and Clinical Medicine.2004, 2

[9]

Plasminogen activator inhibitor type 1: the two faces of the same coin [J].

Hertig, A ;

Rondeau, E .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (01) :39-44

[10]

丹参对血管紧张素Ⅱ诱导的肾小球系膜细胞表达TGF-β1,ROS和PAI-1的影响 [J].

袁军 ;

鲁艳芳 ;

陈陶后 ;

曾祥法 .

中国中药杂志, 2007, (22) :2400-2404

← 1 2 →